Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation
Amyotrophic lateral sclerosis (ALS) is a devastating disease caused by degeneration of
motor neurons. As with all major neurodegenerative disorders, development of disease …
motor neurons. As with all major neurodegenerative disorders, development of disease …
[HTML][HTML] The role of mitochondria in amyotrophic lateral sclerosis
Mitochondria are unique organelles that are essential for a variety of cellular processes
including energy metabolism, calcium homeostasis, lipid biosynthesis, and apoptosis …
including energy metabolism, calcium homeostasis, lipid biosynthesis, and apoptosis …
ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?
D Petrov, C Mansfield, A Moussy… - Frontiers in aging …, 2017 - frontiersin.org
Amyotrophic lateral sclerosis (ALS) is a devastating condition with an estimated mortality of
30,000 patients a year worldwide. The median reported survival time since onset ranges …
30,000 patients a year worldwide. The median reported survival time since onset ranges …
Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease
Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease - Ng, L - 2017 |
Cochrane Library Skip to Content Cookies Our site uses cookies to improve your experience …
Cochrane Library Skip to Content Cookies Our site uses cookies to improve your experience …
The clinical trial landscape in amyotrophic lateral sclerosis—Past, present, and future
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease marked by
progressive loss of muscle function. It is the most common adult‐onset form of motor neuron …
progressive loss of muscle function. It is the most common adult‐onset form of motor neuron …
Interventions for fatigue and weight loss in adults with advanced progressive illness
Background Fatigue and unintentional weight loss are two of the commonest symptoms
experienced by people with advanced progressive illness. Appropriate interventions may …
experienced by people with advanced progressive illness. Appropriate interventions may …
Glial cells—The strategic targets in amyotrophic lateral sclerosis treatment
T Filipi, Z Hermanova, J Tureckova, O Vanatko… - Journal of clinical …, 2020 - mdpi.com
Amyotrophic lateral sclerosis (ALS) is a fatal neurological disease, which is characterized by
the degeneration of motor neurons in the motor cortex and the spinal cord and subsequently …
the degeneration of motor neurons in the motor cortex and the spinal cord and subsequently …
SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments
PI Joyce, P Fratta, EMC Fisher… - Mammalian Genome, 2011 - Springer
Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease with no cure.
Breakthroughs in understanding ALS pathogenesis came with the discovery of dominant …
Breakthroughs in understanding ALS pathogenesis came with the discovery of dominant …
Creatine for neuroprotection in neurodegenerative disease: end of story?
A Bender, T Klopstock - Amino Acids, 2016 - Springer
Creatine (Cr) is a natural compound that plays an important role in cellular energy
homeostasis. In addition, it ameliorates oxidative stress, glutamatergic excitotoxicity, and …
homeostasis. In addition, it ameliorates oxidative stress, glutamatergic excitotoxicity, and …
Electrical impedance myography as a biomarker to assess ALS progression
SB Rutkove, JB Caress, MS Cartwright… - Amyotrophic Lateral …, 2012 - Taylor & Francis
Electrical impedance myography (EIM), a non-invasive, electrophysiological technique, has
preliminarily shown value as an ALS biomarker. Here we perform a multicenter study to …
preliminarily shown value as an ALS biomarker. Here we perform a multicenter study to …